Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombolytic Therapy | 6 | 2026 | 164 | 1.030 |
Why?
|
| Fibrinolytic Agents | 6 | 2025 | 297 | 0.920 |
Why?
|
| Thrombectomy | 4 | 2026 | 78 | 0.790 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2017 | 248 | 0.790 |
Why?
|
| Stroke | 7 | 2026 | 1271 | 0.590 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2025 | 41 | 0.570 |
Why?
|
| Endovascular Procedures | 4 | 2026 | 390 | 0.500 |
Why?
|
| Intracranial Hemorrhages | 2 | 2025 | 106 | 0.480 |
Why?
|
| Cerebral Infarction | 2 | 2014 | 47 | 0.400 |
Why?
|
| beta-Alanine | 1 | 2012 | 25 | 0.360 |
Why?
|
| Antithrombins | 1 | 2012 | 71 | 0.350 |
Why?
|
| Benzimidazoles | 1 | 2012 | 189 | 0.330 |
Why?
|
| Viridans Streptococci | 1 | 2009 | 7 | 0.300 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 96 | 0.290 |
Why?
|
| Endocarditis, Bacterial | 1 | 2009 | 46 | 0.290 |
Why?
|
| Corynebacterium Infections | 1 | 2009 | 43 | 0.280 |
Why?
|
| Cerebral Hemorrhage | 3 | 2015 | 125 | 0.260 |
Why?
|
| Reperfusion | 2 | 2026 | 54 | 0.260 |
Why?
|
| Specialization | 1 | 2008 | 137 | 0.250 |
Why?
|
| Disease Management | 1 | 2011 | 653 | 0.250 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 171 | 0.250 |
Why?
|
| Neurology | 1 | 2008 | 117 | 0.240 |
Why?
|
| Medicine | 1 | 2008 | 125 | 0.240 |
Why?
|
| Heart Arrest | 1 | 2010 | 411 | 0.240 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 558 | 0.230 |
Why?
|
| Cerebral Angiography | 3 | 2026 | 119 | 0.220 |
Why?
|
| Critical Care | 2 | 2020 | 702 | 0.200 |
Why?
|
| Brain Ischemia | 2 | 2020 | 359 | 0.190 |
Why?
|
| Epidemiologists | 1 | 2022 | 5 | 0.180 |
Why?
|
| Sulfatases | 1 | 2021 | 5 | 0.170 |
Why?
|
| Acetylglucosaminidase | 1 | 2021 | 8 | 0.170 |
Why?
|
| Protein Sorting Signals | 1 | 2021 | 21 | 0.170 |
Why?
|
| Morals | 1 | 2022 | 79 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2025 | 697 | 0.160 |
Why?
|
| Lysosomes | 1 | 2021 | 131 | 0.160 |
Why?
|
| Education, Professional | 1 | 2020 | 18 | 0.160 |
Why?
|
| Life Support Care | 1 | 2020 | 42 | 0.150 |
Why?
|
| Treatment Outcome | 10 | 2026 | 11794 | 0.150 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 74 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 2770 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 148 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 8347 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1368 | 0.130 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2017 | 6 | 0.130 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2933 | 0.130 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 68 | 0.120 |
Why?
|
| Sodium Chloride | 1 | 2017 | 138 | 0.120 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2015 | 3 | 0.110 |
Why?
|
| Drainage | 1 | 2017 | 185 | 0.110 |
Why?
|
| Perfusion Imaging | 2 | 2014 | 66 | 0.110 |
Why?
|
| Middle Aged | 13 | 2026 | 36309 | 0.110 |
Why?
|
| Aged | 11 | 2026 | 26217 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 195 | 0.100 |
Why?
|
| Peptides | 1 | 2020 | 999 | 0.100 |
Why?
|
| Thrombin Time | 1 | 2012 | 13 | 0.090 |
Why?
|
| Humans | 20 | 2026 | 145783 | 0.090 |
Why?
|
| Patient Transfer | 1 | 2015 | 211 | 0.090 |
Why?
|
| Dabigatran | 1 | 2012 | 30 | 0.090 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 48 | 0.090 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 53 | 0.090 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 55 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1582 | 0.090 |
Why?
|
| Brain Edema | 1 | 2011 | 62 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 143 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2025 | 2064 | 0.080 |
Why?
|
| Hematoma | 1 | 2011 | 63 | 0.080 |
Why?
|
| Stillbirth | 1 | 2010 | 82 | 0.080 |
Why?
|
| Male | 12 | 2026 | 73011 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 305 | 0.080 |
Why?
|
| Heparin | 1 | 2011 | 247 | 0.070 |
Why?
|
| Female | 13 | 2026 | 79045 | 0.070 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 71 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 196 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 428 | 0.070 |
Why?
|
| Critical Illness | 2 | 2020 | 900 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2011 | 380 | 0.060 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2006 | 1 | 0.060 |
Why?
|
| Choroid Diseases | 1 | 2006 | 10 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 328 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2015 | 924 | 0.060 |
Why?
|
| Brain Stem | 1 | 2006 | 98 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 280 | 0.060 |
Why?
|
| Retinal Diseases | 1 | 2006 | 101 | 0.060 |
Why?
|
| Computed Tomography Angiography | 1 | 2026 | 146 | 0.050 |
Why?
|
| Education, Medical | 1 | 2008 | 276 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 354 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2008 | 900 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 1399 | 0.040 |
Why?
|
| Radiography | 2 | 2015 | 853 | 0.040 |
Why?
|
| Cricetulus | 1 | 2021 | 118 | 0.040 |
Why?
|
| CHO Cells | 1 | 2021 | 169 | 0.040 |
Why?
|
| Cricetinae | 1 | 2021 | 305 | 0.040 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2020 | 18 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 174 | 0.040 |
Why?
|
| Certification | 1 | 2020 | 119 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 2123 | 0.030 |
Why?
|
| Adult | 5 | 2014 | 40881 | 0.030 |
Why?
|
| Pregnancy | 1 | 2010 | 7216 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2025 | 8078 | 0.030 |
Why?
|
| Acute Disease | 1 | 2020 | 1036 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2015 | 17330 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 218 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2013 | 26 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 1151 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1330 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 360 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2011 | 37 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1350 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 6085 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 2028 | 0.020 |
Why?
|
| Amlodipine | 1 | 2006 | 10 | 0.020 |
Why?
|
| Metoprolol | 1 | 2006 | 26 | 0.020 |
Why?
|
| Valsartan | 1 | 2006 | 32 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2006 | 50 | 0.020 |
Why?
|
| Valine | 1 | 2006 | 83 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2006 | 189 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 2410 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 4330 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 1043 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 18356 | 0.010 |
Why?
|
| Adolescent | 2 | 2013 | 22577 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 521 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1782 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 38102 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 14254 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 3916 | 0.010 |
Why?
|